Mary Kerr (NeRRe)

Af­ter sell­ing its spin­out to Bay­er in a $875M-plus deal, NeRRe Ther­a­peu­tics grabs $28M for some 'un­fin­ished busi­ness'

Some biotech CEOs find them­selves out of jobs fol­low­ing a buy­out. Not Mary Kerr.

In fact, af­ter Bay­er dished out $425 mil­lion in cash to buy KaNDy Ther­a­peu­tics and its menopause treat­ment last Au­gust — which was spun out from NeRRe Ther­a­peu­tics and run by that ex­act same team — her en­tire crew quick­ly got back to work.

Like the drug that Bay­er bought (dubbed NT-814), the three oth­er drugs sit­ting in NeRRe’s pipeline are neu­rokinin-tar­get­ing com­pounds that had orig­i­nal­ly hailed from Glax­o­SmithK­line. Among them, orvepi­tant for chron­ic cough was the lead can­di­date, po­si­tioned just slight­ly ahead of NT-814 as the lead can­di­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.